AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06762171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open wedge high tibial osteotomy
Description: All procedures will be performed based on the technique recommended by the AO international knee expert group. Biplanar osteotomy, which comprises osteotomies in the axial and frontal planes, will be performed in all cases. Ascending frontal osteotomy, leaving the tibial tuberosity on the distal fragment, will be also performed. All osteotomies will be performed without the use of additional bone grafts, and the opening of the osteotomy was maintained with a Tomofix plate (Orthomed-E Co., Egypt). Wound closure will be performed in layers.
Study NCT06762171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic partial lateral patellar facetectomy
Description: Diagnostic arthroscopy will be performed in all cases to assess Patellofemoral articular cartilage degeneration , assess the lateral compartment and exclude any other pathology. The knee is taken throughout a range of motion to directly visualize the impingement of the lateral patellar facet against the trochlea. Next, a radiofrequency probe is used to outline the area to be resected along the lateral patellar facet While maintaining the knee at 20 degrees of flexion, a 5.5-mm burr is introduced, and under arthroscopic visualization, the overhanging portion of the lateral patellar facet is carefully resected. Once the bony resection is complete, the knee is dynamically re-evaluated (through flexion and extension) for residual impingement and to assess for improvements in patellar mobility. Patellar tracking is assessed to verify that there is no catching in flexion and that patellar mobility is improved.
Study NCT06760715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an interactive m-health self-management
Description: Description: The experimental group will undergo a lifestyle intervention based on the Transtheoretical Model (TTM), utilizing the MOSAC cloud platform. This intervention focuses on self-management to facilitate behavior changes aimed at weight loss and improving Obstructive Sleep Apnea (OSA) of T2DM patients. Key components include self-monitoring, tracking, real-time feedback, and customized weight loss plans, all enhanced by gamification features. The intervention emphasizes a healthy approach to weight loss, promoting a balanced diet, moderate calorie reduction, and increased physical activity, such as step counts. Each stage of the intervention outlines specific objectives, processes, and measures for achieving behavioral change and supporting healthy weight loss.
Study NCT06760715 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: In the control group
Description: Description: In the control group, standard medical care will continue to be provided along with written educational pamphlets on weight loss and sleep hygiene. The interactive m-health cloud platform will not be offered. However, the results of the three questionnaires administered to each participant will be individually explained, and any questions will be addressed immediately. After the activity concludes, participants may choose to receive the same intervention as the experimental group, if they wish.
Study NCT06761365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LuSeed Aneurysm Embolization System
Description: a permanent intrasaccular implant used for treatment of unruptured intracranial saccular aneurysms (IA) in adult patients according to international guidelines who are indicated for non-emergent endovascular embolization of saccular IAs at the time of presentation.
Study NCT06761326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided infraclavicular approach of subclavian vein cannulation
Description: All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
Study NCT06090513 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Comprehensive Genomic Profile testing; ELIA software; Molecular Genetic Pathologist consultation
Description: TSO500; detect single nucleotide variants (SNV), INDELs, copy number alterations (CNAs), microsatellite instability (MSI), and tumor mutation burden (TMB) in eligible patients; ELIA software to interface clinic EMR to lab; Consultations and molecular tumor boards by molecular genetic pathologist (MGP)
Study NCT06090513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: limited genetic testing or no testing
Description: Minimal genetic testing for eligible patients or treatment without testing
Study NCT05957510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.
Study NCT05957510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: the treatment recommended by the investigator
Study NCT06270524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will be taken for further analysis
Study NCT06270524 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be taken for further analysis
Study NCT05368857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Up to 10 adult healthy volunteers will be enrolled in this study in which small areas of their skin will be exposed to UVR and skin samples taken. UV-induced DNA damage and repair will be analysed.
Study NCT06761326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided infraclavicular approach of subclavian vein cannulation
Description: All patients will be in supine position, with the arm abducted to 45 degrees , the angle of the arm will be increased to 90 degrees to best acquire the image.The probe will be placed in he parasgittal plane in the deltopectoral groove medial to the coracoid process . The image will be optimized regarding the depth , focus and the gain accorgingly for the best image of the axillary artery and vein similar to that acquired when performing an infraclavicular approach for brachial plexus block . The probe will be rotated to obtain a longitudinal image of the axillary vein . The needle will be introduced in real time imaging , in an inplane technique and blood will be aspirated , the guidewire will be introduced in real time imaging.The internal jugular vein will be scanned bilaterally via ultrasonography to exclude malposition of the guidewire and will be reported in case of such. The catheter will be introduced through the sheath and will be tunneled the skin.
Study NCT06761963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Performed using Miha Bodytec equipment, properly calibrated, with electrodes on the quadriceps, hamstrings, glutes, biceps, triceps, pectorals, abdomen, trapezius, latissimus dorsi and quadratus lumborum muscles.
Study NCT06761963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: Pulmonary rehabilitation program.
Study NCT06760962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective Mindfulness and Emotional Regulation training
Description: The RMERT program consisted of six weekly 90-minute sessions facilitated by researchers trained in cognitive behavioral therapy (CBT) and transactional analysis (TA). The training employed the ABC model of CBT (Activating events, Beliefs, and Consequences) to address maladaptive cognitive patterns, along with TA techniques such as empathic inquiry and reflection. Relaxation strategies, including diaphragmatic breathing and progressive muscle relaxation, were also integrated. The sessions focused on enabling students to reflect on their mental and emotional states, process their feelings, and apply cognitive reappraisal-a healthy emotional regulation strategy-instead of relying on expressive suppression, which is maladaptive.
Study NCT06761248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescent Starch Nanoparticles Caries Detection Rinse
Description: The fluorescent starch nanoparticles caries detection rinse is an innovative diagnostic tool designed to enhance the early detection of active dental caries. It contains proprietary fluorescent starch nanoparticles that infiltrate the porous enamel of active caries lesions. Upon illumination with a standard dental curing light, the nanoparticles fluoresce, allowing clinicians to differentiate active caries from inactive lesions and other enamel conditions. This rinse is evaluated as a non-invasive, highly sensitive, and specific diagnostic device.
Study NCT06762093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical repaire
Description: * Primary closure of lacerations~* Eyelid margin repair~* Eyelid crease reconstruction~* Eyelid transposition flaps or grafts~* Tarsorrhaphy
Study NCT06760871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nebulised distilled water
Description: After the surgery, the patients will be admitted to the ward and taken to the bed, and their care and treatment will be applied by the nurse. Afterwards, the researcher will apply cold vapour as an inhaler for 15 minutes. For this application, the stand to which the ultrasonic nebuliser device is connected will be positioned close to the patient's bed. 200 ml of distilled water will be placed in the liquid reservoir of the device. The patient will be given a comfortable position and the device will be adjusted so that the steam hose covers the patient's mouth and nose and the patient will be allowed to inhale the steam through the mouth and nose. After the electrical connection of the device is provided, the device will be started and cold steam application will begin. In the 1st hour, inhaler cold water vapour application will be performed for 15 minutes.
Study NCT06762236 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pillatate Training
Description: .The session will repeated three times per week for 6 weeks with 40-minute sessions In Pilates we include 5 Pilate exercise, The Hundred (Rhythmic Breathing), Single Leg Stretch (Rhythmic Breathing), side kick, Toe Taps (Set Breathing Pattern) ,leg pull front for 6 weeks.
Study NCT06762236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillatate Training
Description: .The session will repeated three times per week for 6 weeks with 40-minute sessions In Pilates we include 5 Pilate exercise, The Hundred (Rhythmic Breathing), Single Leg Stretch (Rhythmic Breathing), side kick, Toe Taps (Set Breathing Pattern) ,leg pull front for 6 weeks.
Study NCT06761859 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Inhalation in Psychiatric Nurses
Description: Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The lavender essential oil to be used in the study will be dropped 3 drops onto a cotton handkerchief cut into a disc shape and fixed to the clothes of the psychiatric nurses, 20 cm away from their noses, and they will be asked to inhale it for 30 minutes.
Study NCT06760689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: One of the videos chosen by the patient will be opened in the virtual reality glasses and will be played for 20 minutes.
Study NCT06760689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale
Description: The patient received standard nursing care. Scales were filled in after the course.
Study NCT06760689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scale
Description: The patient received standard nursing care. Scales were filled in after the course.
Study NCT06760780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The experimental group will first be given a theoretical lesson prepared in line with the current literature on osteoporosis. At the end of the lesson, a prepared scenario example on osteoporosis will be covered.
Study NCT06760780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will only be given a theoretical lesson prepared in line with the current literature on osteoporosis. No other intervention will be made.
Study NCT06762119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cell
Description: CAR-T cell
Study NCT04675684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery-group
Description: The complex intervention are instructions in ruminations-therapy and mindfulness, advice in healthy diets, physical - and social activities and sleep hygiene, and support in smoking cessation, alcohol counseling and medication adherence.
Study NCT04726033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-TLX592
Description: TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592)
Study NCT04860934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Training Program Group
Description: Fifteen patients will receive Dual Task Training Program. Total Period: 8 Weeks.
Study NCT04860934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
Study NCT04860934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
Study NCT04971538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OraQuick® HCV Self-Test
Description: The OraQuick® HCV Self-Test is a lateral flow rapid diagnostic that can detect anti-HCV antibodies in oral fluid. Instructions for Use (IFU) for OraQuick® HCV Rapid Antibody Self-Test have been developed in Georgian for the previous 2 studies conducted in Georgia using the OraQuick® HCV Rapid Antibody Self-Test. The IFU has been optimized taking in the feedback on the IFU resulting from the aforementioned studies. As this HCV test is not approved for self-test use in Georgia, all tests will be labelled as Research Use Only (RUO) and test results will not be used for patient management.
Study NCT03641248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated Devil's Claw
Description: Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Study NCT03641248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-enteric coated Devil's Claw
Description: Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Study NCT05304117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning
Description: Community Information Session and Private Sharing Session with trained social worker
Study NCT05304117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advance Care Planning
Description: Community Information Session and Private Sharing Session with trained social worker
Study NCT06065059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNG348
Description: Ubiquitin Specific Peptidase 1 (USP1) inhibitor
Study NCT06065059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: For premenopausal women: 20 mg or 5 mg tamoxifen orally for postmenopausal women: For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (5 mg) or standard dose (20 mg) of tamoxifen
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: for postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: for postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily,
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrazole
Description: for postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily;
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone + Anastrazole
Description: Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.
Study NCT06075953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-endoxifen
Description: Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.
Study NCT06467357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Standard of care chemotherapy by intravenous infusion
Study NCT06467357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Standard of care chemotherapy by intravenous infusion
Study NCT06467357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Standard of care immunotherapy by intravenous infusion
Study NCT06467357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Experimental therapy by intravenous infusion
Study NCT06467357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Experimental therapy by intravenous infusion
Study NCT06467357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Agilent HercepTest™ mAb pharmDx
Description: A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis).
Study NCT06467357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Agilent HercepTest™ mAb pharmDx
Description: A semi-quantitative immunohistochemical assay to determine HER2 overexpression in FFPE breast cancer tissues routinely processed for histological evaluation.~Based on a primary monoclonal rabbit antibody which visualises Her2 overexpression utilising a fully automated IHC platform (Dako Omnis).
Study NCT06467357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ventana PD-L1 SP263 assay
Description: A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
Study NCT06467357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ventana PD-L1 SP263 assay
Description: A qualitative immunohistochemical assay to determine the level of PD-L1 expression in FFPE non-small cell lung cancer (NSCLC) tissues routinely processed for histological evaluation. Based on a rabbit monoclonal anti-PD-L1 clone SP263 which visualises PD-L1 protein using a VENTANA BenchMark ULTRA instrument
Study NCT05209165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: weekly Semaglutide (increased from starting dose of 0.25 mg at four-week intervals (0.5 mg, 1.0 mg, 1.7 mg) to a target dose of 2.4 mg) for 52 weeks with intake visit for the VA MOVE program
Study NCT05209165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo and intake visit for VA MOVE
Study NCT06633614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supervised prehabilitation programme
Description: Participants will receive standard preoperative physiotherapy education along with a Fitbit Aspire 3 wearable device to track vital signs such as heart rate, physical activity, and sleep patterns. They will follow a personalized exercise program, supervised remotely by a physiotherapist via telemedicine twice a week. The program will include 20-minute sessions at least three times per week, focusing on strength training, aerobic exercises (at 40% of maximal heart rate), and flexibility exercises. Progress will be monitored through vital signs and workout data, with the physiotherapists adjusting the regimen as needed. Participants with low inspiratory pressure (MIP \&amp;lt;100 cmH₂O) will receive an Inspiratory Muscle Trainer (IMT). Additionally, some participants may be provided with a portable cycle pedometer featuring adjustable resistance. To ensure safety, both participants and caregivers will receive a safety briefing, and a 24-hour emergency hotline.